The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Accuracy of interim plasma cell free DNA genotyping for cHL patients
Timeframe: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for DLBCL patients
Timeframe: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for FL patients
Timeframe: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for MCL patients
Timeframe: 24 months from treatment